Sunovion uses familiar moth to refresh Lunesta ads

Share this article:
Sunovion Pharmaceuticals quietly mothballed a Lunesta TV ad that drew FDA scrutiny, in favor of a spot that reprises the sleep drug's familiar mascot.
On air nationally since Thanksgiving, the latest commercial features the Luna moth coming to rest on the backs of those with insomnia, as a voiceover states, “Sleep well, on the wings of Lunesta.” The luna moth has always been featured in Lunesta TV spots, usually at the end. The new spot prominently features it throughout.
Interpublic Group agencies ICC, which is part of Lowe Healthcare, and Deutsch collaborated on the spot.
It's part of a renewed effort to educate patients and physicians on the importance of treating insomnia, said Tricia Moriarty, Sunovion director of commercial communications. She told MM&M that the launch of the new ad “was not related in any way to FDA's concerns but part of a fresh new campaign.”
In June 2010 DDMAC cited a previous Lunesta commercial for misleading claims. That ad featured a woman “fighting for sleep” in a bed-turned-boxing ring and implied superiority over other medications, despite a lack of clinical evidence to that effect, while overstating the mechanism of action, DDMAC wrote.
Moriarty said the boxing-bed ad was updated in July to address the untitled letter, and the revised spot was aired from August-November by the company, then known as Sepracor. Sepracor changed its name to Sunovion in October, a year after being acquired by Japan's Dainippon Sumitomo Pharma.
According to SDI/Kantar Media, for the 12 months ending September 2010, Sepracor increased DTC advertising spend by 78% to about $49 million. That's more than double the $22.9 million spent by Sanofi-Aventis on consumer messaging for rival sleep drug Ambien CR, which cut its spend 86% during the same period. A generic form of Ambien CR was introduced in October.
Lunesta posted third-quarter US sales of $154 million, vs. $151 million in the second quarter. Ambien CR recorded $142 million in US third-quarter sales, and $149 million in the second quarter.
Moriarty said the new ad, which also appears on, may be used in other digital channels, and those decisions will be made at a later date.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete October 2014 Digital Edition

Read the complete October 2014 Digital Edition

Click the above link to access the complete Digital Edition of the October 2014 issue of MM&M, with all text, charts and pictures.

Predicting your pink slip

Predicting your pink slip

Any time a firm needs to save money, high-salaried executives are targets

Private View: New ways to engage with customers

Private View: New ways to engage with customers

These healthcare social media campaigns successfully use emotion, altruism and the human desire to "brand" oneself to get customers engaged.